# A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT01053988** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1031 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** FF/GW642444 Inhalation Powder
- **DRUG:** FF Inhalation Powder
- **DRUG:** GW642444 Inhalation Powder
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01053988
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10-05
- **Primary completion:** 2011-02-01
- **Final completion:** 2011-04-14
- **Target enrollment:** 1031 (ACTUAL)
- **Last updated:** 2018-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01053988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01053988, "A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01053988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*